Identification of Herpesvirus-like DNA Sequences in AIDS-associated Kaposi's Sarcoma

Overview

Journal Science

Specialty Science

Date 1994 Dec 16

PMID 7997879

Citations 1965

Authors

Y Chang

E Cesarman

M S Pessin

F Lee

J Culpepper

D M Knowles

P S Moore

Affiliations

Soon will be listed here.

Abstract

Representational difference analysis was used to isolate unique sequences present in more than 90 percent of Kaposi's sarcoma (KS) tissues obtained from patients with acquired immunodeficiency syndrome (AIDS). These sequences were not present in tissue DNA from non-AIDS patients, but were present in 15 percent of non-KS tissue DNA samples from AIDS patients. The sequences are homologous to, but distinct from, capsid and tegument protein genes of the Gammaherpesvirinae, herpesvirus saimiri and Epstein-Barr virus. These KS-associated herpesvirus-like (KSHV) sequences appear to define a new human herpesvirus.

Citing Articles

Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022.

Morales A, Benson G, Glavan S, Giuliano R, Dickson M Oncologist. 2025; 30(3).

PMID: 40079529 PMC: 11904781. DOI: 10.1093/oncolo/oyaf024.

Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases.

Inagaki T, Espera J, Wang K, Komaki S, Nair S, Davis R bioRxiv. 2025; .

PMID: 40027700 PMC: 11870588. DOI: 10.1101/2025.02.19.639178.

HIV-1 Tat-induced disruption of epithelial junctions and epithelial-mesenchymal transition of oral and genital epithelial cells lead to increased invasiveness of neoplastic cells and the spread of herpes simplex virus and cytomegalovirus.

Tugizov S Front Immunol. 2025; 16:1541532.

PMID: 40018040 PMC: 11866325. DOI: 10.3389/fimmu.2025.1541532.

Unraveling the Kaposi Sarcoma-Associated Herpesvirus (KSHV) Lifecycle: An Overview of Latency, Lytic Replication, and KSHV-Associated Diseases.

Losay V, Damania B Viruses. 2025; 17(2).

PMID: 40006930 PMC: 11860327. DOI: 10.3390/v17020177.

Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.

Ramaswami R, Kask A, DAmico L, Menon M, Lurain K, Yarchoan R J Immunother Cancer. 2025; 13(2).

PMID: 39915263 PMC: 11804200. DOI: 10.1136/jitc-2024-010291.